share_log

Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $3

Chardan Capital Maintains Buy on Vincerx Pharma, Lowers Price Target to $3

查丹資本維持對Vincerx Pharma的買入,將目標價下調至3美元
Benzinga Real-time News ·  2022/11/17 18:01

Chardan Capital analyst Matthew Barcus maintains Vincerx Pharma (NASDAQ:VINC) with a Buy and lowers the price target from $4 to $3.

Chardan Capital分析師馬修·巴庫斯維持Vincerx Pharma(納斯達克:VNC)的買入,並將目標價從4美元下調至3美元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論